Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment
Open Access
- 25 November 2016
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 31 (4) , 529-536
Abstract
Placental growth factor (PlGF) is a member of the VEGF family that plays an important role in experimental models of diabetic retinopathy and retinal neovascularization. We aimed to investigate whether vitreous levels of PlGF correlated with proliferative diabetic retinopathy (PDR) status, VEGF levels, and bevacizumab treatment. We also analysed PDR membranes to confirm the presence of the PlGF receptor, FLT1, in endothelial cells. This was a case-control study: undiluted vitreous fluid samples were obtained from 28 active PDR patients without preoperative bevacizumab treatment, 21 active PDR patients with preoperative bevacizumab treatment, 18 inactive PDR patients, and 21 control patients. PlGF and VEGF levels in samples were determined by enzyme-linked immunosorbent assay. Immunohistochemistry for FLT1 was performed on human PDR membranes. Compared to control, vitreous PlGF levels were higher in both active PDR without bevacizumab (PPP=0.56). Compared to active PDR, PlGF levels were significantly reduced in inactive PDR (P=0.004). PlGF levels were highly correlated with VEGF levels in active PDR. VEGFR1 was expressed in endothelial cells in human PDR membranes. The strong correlation of PlGF levels with PDR disease status and expression of FLT1 in human PDR membranes suggest that PlGF has a pathogenic role in proliferative diabetic retinopathy. Therapeutic targeting of PlGF with agents like aflibercept may be beneficial.Keywords
This publication has 27 references indexed in Scilit:
- Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry‐based studyActa Ophthalmologica, 2014
- Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal Age-Related Macular Degeneration Clinical TrialsOphthalmology, 2014
- Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGFExpert Review of Clinical Pharmacology, 2014
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2014
- EFFECTS OF INTRAVITREAL INJECTION OF BEVACIZUMAB ON INFLAMMATORY CYTOKINES IN THE VITREOUS WITH PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2014
- Vitreous Mediators after Intravitreal Bevacizumab or Triamcinolone Acetonide in Eyes with Proliferative Diabetic RetinopathyOphthalmology, 2009
- Angiogenic Pathways in Diabetic RetinopathyNew England Journal of Medicine, 2005
- Upregulation of placental growth factor by vascular endothelial growth factor via a post‐transcriptional mechanismFEBS Letters, 2005
- Vitreous Levels of Placenta Growth Factor and Vascular Endothelial Growth Factor in Patients With Proliferative Diabetic RetinopathyDiabetes Care, 2002
- Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditionsNature Medicine, 2001